These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 25511800)

  • 1. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
    Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
    BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
    Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of COX-2 expression as prognostic factor in early breast cancer.
    Kargi A; Uysal M; Bozcuk H; Coskun HS; Savas B; Ozdogan M
    J BUON; 2013; 18(3):579-84. PubMed ID: 24065467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
    Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
    PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
    Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG
    Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of TβRII Expression in Breast Cancer.
    Gao N; Zhai Q; Li Y; Huang K; Bian D; Wang X; Liu C; Xu H; Zhang T
    PLoS One; 2015; 10(11):e0141412. PubMed ID: 26551005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
    Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
    Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
    Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
    World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
    Xu F; Li M; Zhang C; Cui J; Liu J; Li J; Jiang H
    Oncotarget; 2017 Jan; 8(4):6003-6012. PubMed ID: 27999206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
    Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
    Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.